International journal of cancer
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma.
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Karin E Smedby, Mats Jerkeman, Caroline E Dietrich
Published: 202510.1002/ijc.70220
Abstract
Studies on mantle cell lymphoma (MCL) emphasize that patients with progression of disease (POD) ≤24 months have inferior prognosis compared to patients with later POD. This population-based study assessed the impact of POD on overall survival (OS) by…
Preview only. Read the full abstract at the source